Analysts Set Expectations for VERV Q1 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV) – William Blair issued their Q1 2026 earnings per share (EPS) estimates for Verve Therapeutics in a note issued to investors on Thursday, February 27th. William Blair analyst M. Minter expects that the company will post earnings of ($0.77) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share. William Blair also issued estimates for Verve Therapeutics’ Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.75) EPS and Q4 2026 earnings at ($0.77) EPS.

Verve Therapeutics (NASDAQ:VERV) last posted its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The firm had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million.

A number of other brokerages also recently commented on VERV. Canaccord Genuity Group increased their price objective on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. HC Wainwright boosted their price target on shares of Verve Therapeutics from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday. Finally, Royal Bank of Canada reduced their price objective on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday, November 6th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $26.00.

Verve Therapeutics Stock Up 2.1 %

NASDAQ:VERV opened at $6.33 on Monday. The company has a fifty day simple moving average of $6.90 and a two-hundred day simple moving average of $6.02. The company has a market cap of $535.92 million, a price-to-earnings ratio of -2.57 and a beta of 1.74. Verve Therapeutics has a 52 week low of $4.30 and a 52 week high of $19.34.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of VERV. GAMMA Investing LLC lifted its stake in shares of Verve Therapeutics by 189.7% during the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock worth $34,000 after purchasing an additional 3,964 shares in the last quarter. IFP Advisors Inc grew its position in shares of Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after acquiring an additional 8,237 shares in the last quarter. Creative Planning bought a new stake in shares of Verve Therapeutics in the 3rd quarter valued at approximately $50,000. BNP Paribas Financial Markets acquired a new position in shares of Verve Therapeutics in the 4th quarter valued at about $50,000. Finally, Erste Asset Management GmbH bought a new stake in shares of Verve Therapeutics in the 3rd quarter worth approximately $56,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.